---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-016562"
form_type: "8-K"
ticker: "IONS"
cik: "0000874015"
company_name: "IONIS PHARMACEUTICALS INC"
filed_at: "2025-04-30T23:59:59+00:00"
generated_at: "2026-05-23T03:09:28.678936+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Ionis Q1 revenue up 10% to $132M; TRYNGOLZA brings $6M, guidance raised >20%

## Summary
- Revenue $132M (+10% YoY); TRYNGOLZA product sales $6M; royalty revenue $64M (SPINRAZA $48M, WAINUA $9M).
- GAAP operating loss $146M (non-GAAP $117M); FY2025 revenue guidance raised to $725-750M from >$600M.
- Donidalorsen PDUFA Aug 21, 2025; olezarsen Phase 3 sHTG data Q3 2025; ION582 Phase 3 Angelman Q2 2025.
- Sapablursen licensed to Ono for $280M upfront; potential $660M milestones plus mid-teen royalties.
- Cash & investments $2.1B at Mar 31; expected ~$1.9B year-end after $280M Q2 inflow.

## SEC filing metadata
- accession: 0001140361-25-016562
- form_type: 8-K
- ticker: IONS
- cik: 0000874015
- company_name: IONIS PHARMACEUTICALS INC
- filed_at: 2025-04-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/874015/000114036125016562/0001140361-25-016562-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874015/000114036125016562/ef20048172_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-016562
- JSON: https://secwatch.observer/filing/0001140361-25-016562.json
- Plain text: https://secwatch.observer/filing/0001140361-25-016562.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.